Treatment Registry
TR-0410 ActiveRecorded September 2026

Compounded tirzepatide

Sold by Neo Soma Healthcare · Injection, vial · every compounded tirzepatide record

Recorded initial charges

First month

$330

first month, including required fees on record. The published monthly rate excludes one-time and annual fees; introductory and conditional rates may change. Some fee details are unverified or unpublished; this sum does not establish the full amount payable.

Medication · Initial purchase · recorded initial monthly payment$330

Added from the figures recorded below.

Price

TermPer monthCharged today
Initial purchase

“Initial Purchase: $330”

Per month$330Charged today$330
Ongoing refill, starting rate for lowest dose

“For Tirzepatide (the active ingredient in Mounjaro and Zepbound), refill rates vary by dose and start at $495 every 4 weeks for the lowest dose.”

Per month$495Charged today$495
Price sources
Visit Neo Soma Healthcare

We earn nothing from this link. It opens Neo Soma Healthcare's website without a paid referral.

History

Fewer than two comparable calendar-month readings are available for a price trend. Day- or week-based supplies, introductory offers and unverified payment terms are not connected in this chart.

  • September 2026 — Entry added to the register

Sourcing and terms

PharmacyStrive Pharmacy, San Antonio TX
PrescriberAsynchronous review
CancellationAll sales are final and no refund will be issued.

Not yet checked: states, membership and consult fee.

Recorded from neosomahealthcare.com. Unlike the price rows above, these carry a summary rather than a word-for-word quotation, so they are not shown in quotation marks.

Notes

  1. 1. September 2026 — Compounded, not FDA-approved: 'Compounded medications prescribed by Neo Soma providers are not FDA-approved.' Also carries a non-GLP-1 sexual health line (Ignios, Connect troches) which is out of scope for this register. Semaglutide is compounded with cyanocobalamin (B12); tirzepatide with glycine and B12, per the FAQ.

Treatment Registry is an independent editorial record. It is not a government registry, a licensing body, or a certification. An entry means we recorded what a company published on a given date. It does not mean we recommend the program, and it does not mean the program is approved by anyone.

This record

Entry
TR-0410
Medication category
compounded tirzepatide
Readings
1

Related records

Other records from Neo Soma Healthcare

All Neo Soma Healthcare programs and terms

Compounded tirzepatide at a similar price

The records either side of this one in the recorded spread. Not a ranking, and not a recommendation — a position among 374 records of the same molecule.

Cite this entry

Treatment Registry. (2026). Neo Soma Healthcare — compounded tirzepatide (TR-0410). Last verified September 2026. Retrieved [your access date], from https://treatmentregistry.com/registry/TR-0410

Replace the bracket with the date you read it. Ours is the date we last checked the figures, which is a different thing and is given separately.